Company Filing History:
Years Active: 2003-2007
Title: The Innovations of Thomas J. Clark, Jr.
Introduction
Thomas J. Clark, Jr. is a notable inventor based in San Diego, California, recognized for his contributions to the field of genetic research. With a total of three patents to his name, his work is primarily focused on the detection of genetic markers related to cancer, specifically prostatic conditions. His innovations play a significant role in advancing medical diagnostics and treatment.
Latest Patents
Clark's most recent patents revolve around nucleic acid sequences that facilitate the detection of various prostate-associated genetic markers. These include critical components such as prostate-specific antigen (PSA), prostate-specific membrane antigen (PSMA), and human kallikrein 2 (hK2). His patents disclose methods for amplifying and detecting these nucleic acids, particularly focused on mRNA. Notably, his work includes methods for identifying the presence of these markers in biological samples that are not directly derived from prostate tissues. This has vast implications for early detection and treatment strategies in cancer care.
Career Highlights
Clark is affiliated with Gen-Probe, Inc., a reputable company at the forefront of molecular diagnostics. His work in such an influential organization not only enhances his professional stature but also ensures that his innovations have practical applications in the medical field.
Collaborations
Throughout his career, Clark has collaborated with distinguished professionals, including Richard C. Harvey. Their collective efforts in research have contributed to significant advancements in the understanding and detection of genetic markers in cancer diagnostics.
Conclusion
Thomas J. Clark, Jr. exemplifies the spirit of innovation through his dedicated work in genetic research. His contributions to identifying cancer markers have the potential to revolutionize diagnostics and improve patient outcomes. As he continues his work at Gen-Probe, Inc., his future endeavors are likely to yield further breakthroughs in the field of molecular diagnostics.